Maternal serum markers. Estimation of the risk of Down's syndrome: a prospective study

1994 ◽  
Vol 24 (1) ◽  
pp. 49-53 ◽  
Author(s):  
Giuliana Mancini ◽  
Marco Perona ◽  
Daniela Dall'Amico ◽  
Carla Bollati ◽  
Fulvia Albano ◽  
...  
Keyword(s):  
Prospective Study ◽  
Down's Syndrome ◽  
Down’S Syndrome ◽  
Serum Markers ◽  
Maternal Serum ◽  
A Prospective Study

EFFECT OF GRAVIDITY ON MATERNAL SERUM MARKERS FOR DOWN'S SYNDROME

1996 ◽  
Vol 16 (4) ◽  
pp. 319-322 ◽  
Author(s):  
G. BARKAI ◽  
B. GOLDMAN ◽  
L. RIES ◽  
R. CHAKI ◽  
H. CUCKLE
Keyword(s):  
Down's Syndrome ◽  
Down’S Syndrome ◽  
Serum Markers ◽  
Maternal Serum

scholarly journals Screening for Down's Syndrome: The First Two Years Experience in Bristol

1995 ◽  
Vol 2 (4) ◽  
pp. 207-210 ◽  
Author(s):  
D J Goldie ◽  
J P Astley ◽  
J M Beaman ◽  
D A Bickley ◽  
A Gunneberg ◽  
...  
Keyword(s):  
False Positive Rate ◽  
Down's Syndrome ◽  
Down’S Syndrome ◽  
District General Hospital ◽  
Serum Marker ◽  
Serum Markers ◽  
Maternal Serum ◽  
Age Related ◽  
Related Risk ◽  
Positive Rate

Objectives – To evaluate the effectiveness of a programme for antenatal screening for Down's syndrome using a fetoprotein and total human chorionic gonadotrophin as maternal serum markers. Setting –A district general hospital providing a screening service to a local purchasing authority and (under contract) to another purchasing authority in the same region. Methods – Patients were counselled and screened between 15 and 20 weeks gestation and Down's risk estimates calculated using the maternal serum marker results as modifiers of the age related risk. Outcome was determined in collaboration with the Regional Cytogenetics Unit. Outcome Measures – Detection rate for Down's syndrome, false positive rate, uptake of screening, and uptake of amniocentesis. Results– In two years 22 816 women were screened (approximately 84% of population); 32 Down's pregnancies were identified, 19 (59.4%) had a reported risk of ≥1:250 and 20 (62.5%) a reported risk of ≥1:300. Of those screened before 17 weeks, 16/20 (80%) had a reported risk of ≥1: 300 compared with 4/12 (33%) of those screened later (P = 0.008); 4.64% of patients screened had reported risks ≥1: 250 and 5.87% reported risks of ≥ 1:300. Amniocentesis uptake was 70% in patients with reported risks of ≥ 1:300. Conclusions –Overall the screening programme was effective but screening before 17 weeks was very much more effective than screening later.

scholarly journals Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A

1998 ◽  
Vol 5 (3) ◽  
pp. 115-119 ◽  
Author(s):  
J E Haddow ◽  
G E Palomaki ◽  
G J Knight ◽  
D L Foster ◽  
L M Neveux
Keyword(s):  
Down's Syndrome ◽  
Down’S Syndrome ◽  
The United States ◽  
Serum Markers ◽  
Maternal Serum ◽  
Human Chorionic Gonadotrophin ◽  
Second Trimester ◽  
Serum Samples ◽  
Inhibin A ◽  
Screening Performance

Objectives To determine the second trimester Down's syndrome screening performance of maternal serum dimeric inhibin A, both alone and in combination with existing serum markers. Setting A case-control set of serum samples from patients with Down's syndrome (52) and subjects with matched unaffected pregnancies obtained in a previous cohort study before second trimester amniocentesis and karyotyping. The amniocenteses were performed for reasons other than a positive serum screening test result. Methods For each serum from a Down's syndrome pregnancy, five serum samples from pregnancies with a normal karyotype were matched for recruitment centre, gestational age, maternal age, and date of amniocentesis. A specific form of inhibin (dimeric inhibin A) was measured using monoclonal antibodies. Measurements of α fetoprotein, unconjugated oestriol, and human chorionic gonadotrophin and its free β subunit were already available. Screening performance was modelled using distribution variables of the analytes coupled with the 1993 age distribution of pregnant women in the United States. Results The median dimeric inhibin A level was 2.10 times higher in Down's syndrome pregnancies. When dimeric inhibin A was combined with maternal age and three other serum markers (α fetoprotein, unconjugated oestriol, and human chorionic gonadotrophin) the Down's syndrome detection rate increased to 75% (from 66%) at a 5% false positive rate. If dimeric inhibin A could be added for less than $31 (ranging from $16 to $39 depending on the detection rate, markers chosen, and method of dating), the cost of detecting each Down's syndrome pregnancy and the number of procedure related fetal losses would both be reduced. Conclusions The addition of dimeric inhibin A to prenatal screening programmes for Down's syndrome should be considered, or possibly it could be substituted for an existing serum marker. One barrier to implementation in the United States, however, is the unavailability of kits with Food and Drug Administration approval.

Screening for fetal Down's syndrome with maternal serum markers—an experience in italy

1991 ◽  
Vol 11 (4) ◽  
pp. 245-252 ◽  
Author(s):  
Giuliana Mancini ◽  
Marco Perona ◽  
Daniela Dalľamico ◽  
Carla Bollati ◽  
Fulvia Albano ◽  
...  
Keyword(s):  
Down's Syndrome ◽  
Down’S Syndrome ◽  
Serum Markers ◽  
Maternal Serum

Prenatal Screening for Down's Syndrome with Use of Maternal Serum Markers

1992 ◽  
Vol 327 (9) ◽  
pp. 588-593 ◽  
Author(s):  
James E. Haddow ◽  
Glenn E. Palomaki ◽  
George J. Knight ◽  
Josephine Williams ◽  
Andrea Pulkkinen ◽  
...  
Keyword(s):  
Prenatal Screening ◽  
Down's Syndrome ◽  
Down’S Syndrome ◽  
Serum Markers ◽  
Maternal Serum
Sign in / Sign up

Export Citation Format

Share Document